ALE 26015

Drug Profile

ALE 26015

Latest Information Update: 22 Nov 2000

Price : $50

At a glance

  • Originator NPS Pharmaceuticals; Pharm-Eco Laboratories
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 22 Nov 2000 Discontinued-I for Alzheimer's disease in United Kingdom (PO)
  • 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
  • 25 Jan 1999 Phase-I clinical trials for Alzheimer's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top